Modulation of the Major Histocompatibility Complex Class II–Associated Peptide Repertoire by Human Histocompatibility Leukocyte Antigen (Hla)-Do

Antigen presentation by major histocompatibility complex class II molecules is essential for antibody production and T cell activation. For most class II alleles, peptide binding depends on the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is selectively expressed in B cells and impedes the activity of DM, yet its physiological role remains unclear. Cell surface iodination assays and mass spectrometry of major histocompatibility complex class II–eluted peptides show that DO affects the antigenic peptide repertoire of class II. DO generates both quantitative and qualitative differences, and inhibits presentation of large-sized peptides. DO function was investigated under various pH conditions in in vitro peptide exchange assays and in antigen presentation assays using DO− and DO+ transfectant cell lines as antigen-presenting cells, in which effective acidification of the endocytic pathway was prevented with bafilomycin A1, an inhibitor of vacuolar ATPases. DO effectively inhibits antigen presentation of peptides that are loaded onto class II in endosomal compartments that are not very acidic. Thus, DO appears to be a unique, cell type–specific modulator mastering the class II–mediated immune response induced by B cells. DO may serve to increase the threshold for nonspecific B cell activation, restricting class II–peptide binding to late endosomal compartments, thereby affecting the peptide repertoire.

[1]  C. Théry,et al.  A role for HLA‐DO as a co‐chaperone of HLA‐DM in peptide loading of MHC class II molecules , 1998, The EMBO journal.

[2]  J. Trowsdale,et al.  Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. , 1994, Science.

[3]  E. Unanue,et al.  Distinct antigen MHC class II complexes generated by separate processing pathways. , 1996, The EMBO journal.

[4]  D. Fremont,et al.  Crystal structure of mouse H2-M. , 1998, Immunity.

[5]  Partho Ghosh,et al.  The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3 , 1995, Nature.

[6]  L. Lampson,et al.  Two populations of Ia-like molecules on a human B cell line. , 1980, Journal of immunology.

[7]  M. Karas,et al.  Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. , 1988, Analytical chemistry.

[8]  J. Trowsdale,et al.  Association between HLA-DM and HLA-DR in vivo. , 1996, Immunity.

[9]  E. Williamson,et al.  Cutting edge: signals from the B lymphocyte antigen receptor regulate MHC class II containing late endosomes. , 1998, Journal of immunology.

[10]  O. Bakke,et al.  MHC class II-associated invariant chain contains a sorting signal for endosomal compartments , 1990, Cell.

[11]  D. Weber,et al.  DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. , 1995, Immunity.

[12]  N. Copeland,et al.  Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. , 1996, Immunity.

[13]  G. Hämmerling,et al.  Editing of the HLA‐DR‐peptide repertoire by HLA‐DM. , 1996, The EMBO journal.

[14]  Jeffrey A. Shaman,et al.  An essential role for HLA–DM in antigen presentation by class II major histocompatibility molecules , 1994, Nature.

[15]  J. Trowsdale,et al.  HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading , 1997, Current Biology.

[16]  D. Zaller,et al.  The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. , 1998, Immunity.

[17]  C. Harding,et al.  Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. , 1997, Journal of immunology.

[18]  A. Lanzavecchia,et al.  Mechanisms of antigen uptake for presentation. , 1996, Current opinion in immunology.

[19]  P. Cresswell,et al.  Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding , 1990, Nature.

[20]  J. Trowsdale,et al.  Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs , 1996, The Journal of experimental medicine.

[21]  M. Jackson,et al.  HLA‐DO is a lysosomal resident which requires association with HLA‐DM for efficient intracellular transport. , 1996, The EMBO journal.

[22]  Eric O Long,et al.  Peptide loading onto recycling HLA‐DR molecules occurs in early endosomes , 1998, European journal of immunology.

[23]  Eric O Long,et al.  DO beta: a new beta chain gene in HLA‐D with a distinct regulation of expression. , 1985, The EMBO journal.

[24]  J. Drijfhout,et al.  Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. , 1992, Journal of immunology.

[25]  P. Cresswell,et al.  In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. , 1994, Immunity.

[26]  V. Gnau,et al.  Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules , 1995, The Journal of experimental medicine.

[27]  H. Horstmann,et al.  Intracellular transport and localization of major histocompatibility complex class II molecules and associated invariant chain , 1991, The Journal of cell biology.

[28]  P. Cresswell,et al.  HLA-DM induces clip dissociation from MHC class II αβ dimers and facilitates peptide loading , 1995, Cell.

[29]  C. Benoist,et al.  Mice Lacking H2-M Complexes, Enigmatic Elements of the MHC Class II Peptide-Loading Pathway , 1996, Cell.

[30]  B. Evavold,et al.  Enhanced Dissociation of HLA-DR-Bound Peptides in the Presence of HLA-DM , 1996, Science.

[31]  D. Zaller,et al.  Mediation by HLA-DM of dissociation of peptides from HLA-DR , 1995, Nature.

[32]  Stephen A. Martin,et al.  Delayed extraction matrix‐assisted laser desorption time‐of‐flight mass spectrometry , 1995 .

[33]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[34]  P. Chavrier,et al.  Different endocytic compartments are involved in the tight association of class II molecules with processed hen egg lysozyme and ribonuclease A in B cells. , 1995, Journal of cell science.

[35]  P. Cresswell,et al.  Negative regulation by HLA-DO of MHC class II-restricted antigen processing. , 1997, Science.

[36]  P. A. Peterson,et al.  Altered antigen presentation in mice lacking H2-O. , 1998, Immunity.

[37]  B. Arp,et al.  HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells , 1994, Nature.

[38]  J. Trowsdale,et al.  HLA-DM and MHC class II molecules co-distribute with peptidase-containing lysosomal subcompartments. , 1996, International immunology.

[39]  P. Cresswell,et al.  HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. , 1995, Cell.

[40]  K. Altendorf,et al.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Cresswell,et al.  Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. , 1994, Immunity.

[42]  L. Smith,et al.  A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex , 1991, The Journal of experimental medicine.

[43]  Roger Y. Tsien,et al.  Improved green fluorescence , 1995, Nature.

[44]  J. Bodmer,et al.  Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens. , 1983, Immunology.

[45]  Eric O Long,et al.  Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. , 1994, Journal of immunology.

[46]  H. Ruley,et al.  H2-M Mutant Mice Are Defective in the Peptide Loading of Class II Molecules, Antigen Presentation, and T Cell Repertoire Selection , 1996, Cell.

[47]  R. Mitchell,et al.  Intracellular targeting of antigens internalized by membrane immunoglobulin in B lymphocytes , 1995, The Journal of experimental medicine.

[48]  M. Zacheis,et al.  Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. , 1995, Journal of immunology.

[49]  F. Levine,et al.  HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants , 1985, The Journal of experimental medicine.